AC Immune SA (ACIU)

Etorro trading 970x250
AC Immune SA (ACIU) Logo

About AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer’s disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland. Address: Building B, Lausanne, Switzerland, 1015

AC Immune SA News and around…

Latest news about AC Immune SA (ACIU) common stock and company :

10 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
15 Nov, 2021 Yahoo! Finance

In this article, we discuss the 10 best biotech stocks to buy according to Mark Lampert. You can skip our detailed analysis of Lampert’s Biotechnology Value Fund, and go directly to the 5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark Lampert is an American investor who founded BVF Partners Ltd. […]

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
12 Nov, 2021 Yahoo! Finance

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development LAUSANNE, Switzerland, Nov. 12, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today presented new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosph

76 Biggest Movers From Yesterday
11 Nov, 2021 FinancialContent

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per ...

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease
10 Nov, 2021 Yahoo! Finance

Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo Benefit of semorinemab on ADAS-Cog11 in all prespecified subgroups was consistent with the treatment effect in the overall cohort, regardless of disease severity, baseline Tau load, and ApoE carrier status Benefit on cognition was driven primarily by the memory d

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To ...

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

4 Top Biotech Stocks To Watch This Week
08 Nov, 2021 FinancialContent
AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates
08 Nov, 2021 Yahoo! Finance

AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
08 Nov, 2021 FinancialContent

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update
08 Nov, 2021 Yahoo! Finance

Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease Closed its strategic acquisition of an industry-leading Parkinson’s disease vaccine and an equity financing led by key investors Appointed Monica Shaw, M.D., and Prof. Monika Bütler, Dr. Oec., to the Board of Directors Strong financial position of CHF 188.6 million1 ensures the Company is fully financed through at least Q1 2024 LAUSANNE, Switzerland, Nov. 08, 2021 (GLOBE

26 Stocks Moving in Monday's Pre-Market Session
08 Nov, 2021 FinancialContent

Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science ...

AC Immune says number of families affected by Alzheimer's could nearly triple by 2050
07 Nov, 2021 Yahoo! Finance

Alzheimer's drug developer AC Immune expects the number of families to be affected by the degenerative disease could nearly triple by 2050 to 150 million, its CEO said in an interview with a German magazine. The company recently secured a multi-million investment from the main backers of German COVID-19 vaccine developer BioNTech while acquiring a possible Parkinson's disease vaccine. AC Immune's CEO Andrea Pfeifer, in an interview with German business magazine Wirtschaftswoche published in its online edition on Sunday, described Alzheimer's, a non-curable disease the origin of which is not known, as "a slow pandemic rolling towards the world".

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
05 Nov, 2021 Yahoo! Finance

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases
04 Nov, 2021 Yahoo! Finance

LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is extending its research partnership with leading scientists at the Center for Neurodegenerative Disease Research at the Perelman School of Medicine at the University of Pennsylvania (Penn). The partnership is focused on studying the pathological mechanism of transactive respo

ACIU Crosses Above Key Moving Average Level
02 Nov, 2021 FinancialContent

In trading on Tuesday, shares of AC Immune SA (ACIU) crossed above their 200 day moving average of $7.05, changing hands as high as $7.14 per share. AC Immune SA shares are currently trading up about 6.2% on the day..

New Data on AC Immune’s Abeta and pTau Clinical Programs in Alzheimer’s Disease To Be Presented at CTAD 2021
02 Nov, 2021 Yahoo! Finance

LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimer’s disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimer’s Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021. Scie

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors
29 Oct, 2021 Yahoo! Finance

Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading Swiss economist and former Vice President of the independent Swiss COVID-19 Science Taskforce LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that

Analysts Predict 29% Gains Ahead For BIB
26 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $117.34 per unit.

AC Immune to Present at the Jefferies London Healthcare Conference
25 Oct, 2021 Yahoo! Finance

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. During the fireside chat, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company

Shareholders in AC Immune (NASDAQ:ACIU) are in the red if they invested five years ago
24 Oct, 2021 Yahoo! Finance

We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...

Implied IBB Analyst Target Price: $202
23 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Biotechnology ETF (IBB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $201.55 per unit.

AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year
03 Sep, 2021 FinancialContent
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
02 Sep, 2021 FinancialContent
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
01 Sep, 2021 Yahoo! Finance

AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%

Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More
01 Sep, 2021 Yahoo! Finance

Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

55 Biggest Movers From Yesterday
01 Sep, 2021 FinancialContent

Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. ...

Most Active Stocks Today? 5 Health Care Stocks To Know
31 Aug, 2021 FinancialContent
What Leerink, Wainwright Have To Say For This Alzheimer's Focused Firm
31 Aug, 2021 FinancialContent

Earlier today,AC Immune SA(NASDAQ: ACIU) announcedsemorinemab met one of its co-primary endpointsin a ...

Mid-Afternoon Market Update: Spok Holdings Surges On Takeover Offer; Sequential Brands Shares Slide
31 Aug, 2021 FinancialContent

Toward the end of trading Tuesday, the Dow traded down 0.09% to 35,366.93 while the NASDAQ fell 0.02% to 15,263.43. The S&P also ...

AC Immune SA (ACIU) is a NASDAQ Common Stock listed in , ,

970x250